Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

NCT07034690

Status	RECRUITING
Phase	Phase 4
Sponsor	Novartis Pharmaceuticals
Enrollment	326 participants

Key Eligibility Criteria

Inclusion (11)

- Diagnosis of ASCVD (coronary heart disease, peripheral arterial disease and/or cerebrovascular disease)
- High risk or very high risk for cardiovascular events (as per the 2019 ESC/EAS guidelines \[1\] for the management of dyslipidemias)
- Lipid levels:
- High risk: LDL-C e70 mg/dl (or \> 1.8 mmol/L) or non-HDL-C e100 mg/dl
- Very high risk: LDL-C e55 mg/dl (or \> 1.4 mmol/L) or non-HDL-C e85 mg/dl

... and 6 more (see full listing online)

Exclusion (6)

- Any surgical or medical condition, which in the opinion of the Investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study.
- Unwillingness or inability (e.g., physical or cognitive) to comply with study procedures (including adherence to study visits).
- Participation in any other interventional study.
- Inability to travel to study sites for in-person clinic visits.
- Responsible physician clinical decision not to engage the identified patient.

... and 1 more (see full listing online)

Locations (1 total)

Novartis Investigative Site, Abu Dhabi, United Arab Emirates